CGCarlos Roberto Galia

Carlos Roberto Galia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Roberto Galia has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Characterization of Leukocyte-Rich Platelet-Rich Plasma (L-PRP) and Injectable Platelet-Rich Fibrin (i-PRF): A Laboratory Study

    by André Vinicius Saueressig Kruel, Mariângela Ferreira, Daiane Agostini, Cristiano Valter Diesel, Marcelo Queiroz, Carlos Roberto Galia, Guilherme Liberato da Silva, Stephany Huber, Fernanda Majolo

    Introduction: Orthobiologics such as Platelet-Rich Plasma (PRP) and Injectable Platelet-Rich Fibrin (i-PRF) have emerged as promising tools in regenerative medicine. However, the lack of methodological standardization and the still limited comparative characterization between these products represent significant barriers to their optimized clinical application. This comparative laboratory study aimed to characterize and differentiate PRP and i-PRF, focusing on their cellular composition, obtained volume, and total Platelet-Derived Growth Factor (PDGF-BB) content. Materials and Methods: This study was conducted with 34 individuals meeting standard blood donation criteria. Peripheral blood samples were collected from all participants. PRP was obtained using a modified double-spin centrifugation protocol, whereas i-PRF was prepared using a modified low-speed centrifugation technique. Cellularity (platelet and leukocyte counts), final produced volume, and total PDGF-BB content were assessed using complete blood count analysis and an enzyme-linked immunosorbent assay (ELISA), respectively. Statistical analysis was performed using Linear Mixed Models (LMMs). Results: Both protocols resulted in significant increases in platelet and leukocyte concentrations compared to baseline values. PRP showed significantly higher platelet and leukocyte concentrations compared with i-PRF, as well as markedly higher PDGF-BB levels. In contrast, i-PRF yielded a substantially greater final volume and enabled a higher absolute delivery of total leukocytes, whereas PRP delivered a greater absolute number of platelets. In exploratory analyses, female sex, the presence of comorbidities, and increased abdominal circumference were associated with variations in product volume and cellular composition. Discussion: These findings indicate that PRP and i-PRF exhibit distinct biological profiles in terms of cellularity, volume, and total PDGF-BB content. Whether these laboratory differences translate into distinct clinical outcomes remains unknown. The results should therefore be viewed as hypothesis-generating: they suggest that PRP and i-PRF may not be interchangeable, and that future randomized clinical trials are needed to define product-specific indications based on the target tissue and desired biological mechanism.


  • Open Access

    Comparative Characterization of Leukocyte-Rich Platelet-Rich Plasma (L-PRP) and Injectable Platelet-Rich Fibrin (i-PRF): A Laboratory Study

    by André Kruel, Mariângela Ferreira, Daiane Agostini, Cristiano Diesel, Marcelo Queiroz, Carlos Galia, Guilherme Silva, Stephany Huber, Fernanda Majolo

    Introduction: Orthobiologics such as Platelet-Rich Plasma (PRP) and Injectable Platelet-Rich Fibrin (i-PRF) have emerged as promising tools in regenerative medicine. However, the lack of methodological standardization and the still limited comparative characterization between these products represent significant barriers to their optimized clinical application. This comparative laboratory study aimed to characterize and differentiate PRP and i-PRF, focusing on their cellular composition, obtained volume, and concentration of Platelet-Derived Growth Factor (PDGF-BB). Materials and Methods: This study was conducted with 34 healthy individuals. Peripheral blood samples were collected from all participants. PRP was obtained using a modified double-spin centrifugation protocol, whereas i-PRF was prepared using a modified low-speed centrifugation technique. Cellularity (platelet and leukocyte counts), final produced volume, and PDGF-BB concentration were assessed using complete blood count analysis and enzyme-linked immunosorbent assay (ELISA), respectively. Statistical analysis was performed using Generalized Linear Models (GLM). Results: Both protocols resulted in significant increases in platelet and leukocyte concentrations compared to baselines values. PRP showed significantly higher platelet and leukocyte concentrations compared with i-PRF, as well as markedly higher PDGF-BB levels. In contrast, i-PRF yielded a substantially greater final volume and enabled a higher absolute delivery of total leukocytes, whereas PRP delivered a greater absolute number of platelets. Female Sex, presence of comorbidities, and increased abdominal circumference positively influenced product volume and cellular composition. Discussion: Although both PRP and i-PRF effectively concentrate blood-derived components, they present distinct biological profiles regarding cellularity, volume, and growth factor availability. These findings indicate that PRP and i-PRF are not interchangeable, and their clinical use should be guided by the target tissue, therapeutic mechanism, and evidence from randomized clinical trials.